{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Enrollment was terminated prematurely due to manufacturing shortages of Doxil and Denileukin Diftitox (Ontak). All eligible patients who received at least one dose of study regimen were included in the analyses"},"pointOfContact":{"email":"LKaplan@ucsf.edu","organization":"University of California, San Francisco","phone":"(415) 353-2661","title":"Lawrence Kaplan, MD"}}